- 中国精品科技期刊
- 中国高校百佳科技期刊
- 中国中文核心期刊
- 中国科学引文数据库核心期刊
| Citation: |
WANG Yongjian, GUO Ming. Design, synthesis and structure-activity relationship of a series of novel BCR-ABL inhibitors[J]. J China Pharm Univ, 2024, 55(3): 357 − 366. DOI: 10.11665/j.issn.1000-5048.2023042302
|
In this study, molecular skeleton I N-phenylindoline-5-formamide was obtained by optimizing the structure of the existing allosteric BCR-ABL inhibitor asciminib. Based on this molecular skeleton, compounds 1-12 were designed and synthesized assisted by molecular docking. After characterizing their structures using ESI-MS and NMR, the anti-BCR-ABL1-dependent Luc-Ba/F3 cell proliferation activity of the target compounds in vitro was determined by CCK-8 assay. Finally, highly active lead compound 1 was screened out. For high clearance rate and short half-life period exposed in subsequent druggability evaluation, its druggability was optimized by introducing hydrophilic groups. Afterwards, compounds 13-22 were designed and synthesized. Compound 17 presented high cell inhibitory activity, low clearance rate and long half-life, and is expected to be used as a clinical candidate for further evaluation of biological activity and druggability.
| [1] |
Burmeister T, Schwartz S, Bartram CR, et al. Patients′ age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group[J]. Blood, 2008, 112(3): 918-919.
|
| [2] |
Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy[J]. J Hematol Oncol, 2018, 11(1): 84.
|
| [3] |
Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype[J]. Blood, 1996, 88(7): 2375-2384.
|
| [4] |
Ren RB. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia[J]. Nat Rev Cancer, 2005, 5(3): 172-183.
|
| [5] |
Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia[J]. Blood, 2009, 113(8): 1619-1630.
|
| [6] |
Schoepfer J, Jahnke W, Berellini G, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1[J]. J Med Chem, 2018, 61(18): 8120-8135.
|
| [7] |
Deng XM, Okram B, Ding Q, et al. Expanding the diversity of allosteric bcr-abl inhibitors[J]. J Med Chem, 2010, 53(19): 6934-6946.
|
| [8] |
Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure[J]. N Engl J Med, 2019, 381(24): 2315-2326.
|
| [9] |
Cui YW, Zhao RX, Han LL, et al. Advances in the study of new BCR-ABL kinase inhibitors[J]. Acta Pharm Sin (药学学报), 2023, 58(2): 258-273.
|
| [10] |
Robert MC. FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia[EB/OL]. Washington D. C. : Food and Drug Administration, (2021-10-29)[2023-07-24].https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia.
|
| [11] |
Jiang Q, Li ZR, Qin YZ, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial[J]. J Hematol Oncol, 2022, 15(1): 113.
|
| [12] |
Ruan TT, Ju WJ, Xiong HW, et al. Advances in methodologies for predicting metabolic stability for low-clearance drugs[J]. J China Pharm Univ (中国药科大学学报), 2019, 50(2): 152-160.
|
| [13] |
Huang JK, He LQ, Huang P, et al. Synthesis and biological evaluation of aminoalcohol rheinate as anti-osteosarcoma agents[J]. Acta Pharm Sin (药学学报), 2018, 53(2): 249-255.
|
| [1] | REN Weijie, CEN Lifang, ZOU Yi. Research progress of Bruton's tyrosine kinase (BTK) inhibitors in the treatment of inflammatory and immune-mediated diseases[J]. Journal of China Pharmaceutical University, 2024, 55(1): 63-72. DOI: 10.11665/j.issn.1000-5048.2023121103 |
| [2] | YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615 |
| [3] | BU Hong, ZHOU Jinpei, ZHANG Huibin. Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403 |
| [4] | ZHAO Limeng, WANG Shuzhen. Therapeutic applications of small molecule kinase inhibitors in liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(2): 147-157. DOI: 10.11665/j.issn.1000-5048.20180203 |
| [5] | YUAN Zhong, CHEN Zhuo, LI Qianbin, HU Gaoyun. Advances in research of protein tyrosine phosphatase 1B and its inhibitors[J]. Journal of China Pharmaceutical University, 2018, 49(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20180101 |
| [6] | LI Tonghui, GUO Hao, LU Tao, WANG Yue, LU Shuai, TANG Weifang. Advances in the research of FLT3 inhibitors for acute myeloid leukemia[J]. Journal of China Pharmaceutical University, 2015, 46(2): 153-161. DOI: 10.11665/j.issn.1000-5048.20150203 |
| [7] | ZHANG Yuan, CHENG Yulan, ZHOU Jinpei, ZHANG Huibin. Advances on receptor tyrosine kinase inhibitors taking c-Met as anti-tumor target[J]. Journal of China Pharmaceutical University, 2015, 46(1): 16-27. DOI: 10.11665/j.issn.1000-5048.20150102 |
| [8] | HUANG Fei, ZHU Haijing, ZHOU Xiang, LU Tao, JIAO Yu, TANG Weifang. Progress of Bruton′s tyrosine kinase(BTK)and its inhibitors[J]. Journal of China Pharmaceutical University, 2014, 45(6): 617-624. DOI: 10.11665/j.issn.1000-5048.20140602 |
| [9] | ZHU Yaqi, YAN Fang, DI Bin, YAN Jia, LI Jiachang, LI Yunman. Inhibiting effect of emodin on adriamycin-resistance of K562/ADM cell line[J]. Journal of China Pharmaceutical University, 2014, 45(4): 462-468. DOI: 10.11665/j.issn.1000-5048.20140414 |
| [10] | DONG Gaochao, ZHOU Xiang, TANG Weifang, LU Tao. Advances in the research and development of B-Raf inhibitors[J]. Journal of China Pharmaceutical University, 2014, 45(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20140101 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Total visits：292836
DownLoad: